The most prevalent dementia-causing neurodegenerative condition is Alzheimer’s disease (AD). The aberrant buildup of amyloid β and tau hyperphosphorylation are the two most well-known theories about the mechanisms underlying AD development. However, a significant number of pharmacological clinical studies conducted around the world based on the two aforementioned theories have not shown promising outcomes, and AD is still not effectively treated. Ferroptosis, a non-apoptotic programmed cell death defined by the buildup of deadly amounts of iron-dependent lipid peroxides, has received more attention in recent years. A wealth of data is emerging to support the role of iron in the pathophysiology of AD. Cell line and animal studies applying ferroptosis modulators to the treatment of AD have shown encouraging results. Based on these studies, we describe in this review the underlying mechanisms of ferroptosis; the role that ferroptosis plays in AD pathology; and summarise some of the research advances in the treatment of AD with ferroptosis modulators. We hope to contribute to the clinical management of AD.

中文翻译：

---

铁死亡：阿尔茨海默病的潜在治疗靶点

最常见的导致痴呆的神经退行性疾病是阿尔茨海默病（AD）。β 淀粉样蛋白的异常积累和 tau 蛋白过度磷酸化是关于 AD 发展机制的两个最著名的理论。然而，基于上述两种理论在世界范围内开展的大量药理临床研究并未显示出良好的结果，AD仍未得到有效治疗。铁死亡是一种非凋亡性程序性细胞死亡，其定义是致命量的铁依赖性脂质过氧化物的积累，近年来受到更多关注。大量数据的出现支持了铁在 AD 病理生理学中的作用。应用铁死亡调节剂治疗 AD 的细胞系和动物研究显示出令人鼓舞的结果。基于这些研究，我们在这篇综述中描述了铁死亡的潜在机制；铁死亡在 AD 病理学中的作用；并总结了铁死亡调节剂治疗AD的一些研究进展。我们希望为AD的临床管理做出贡献。